US Opens Section 301 Probe into Germany's Drug-Pricing PolicyA · FULL TRANSLATION

The USTR opened a Section 301 investigation into Germany's drug-pricing policy. Section 301 is a US unilateral tool for probing and retaliating against alleged unfair trade, long used against targets like China; aiming it at ally Germany's drug pricing shows US-Europe friction on pharma and trade heating up. It reflects a broader trend: trade disputes are spreading from tariffs and goods into deeper policy areas like drug prices, subsidies and regulation — and sparing no one, friend or foe. For Taiwanese exporters, it is a warning that in an age of rising protectionism and unilateralism, trade-rule uncertainty is climbing across the board, even between the US and Europe.